期刊文献+

复发性外阴阴道念珠菌病预防性治疗初探 被引量:11

Probe into the preventive treatment of recurrent vulvovaginal candidiasis
在线阅读 下载PDF
导出
摘要 目的:探讨复发性外阴阴道念珠菌病(RVVC) 的预防性治疗效果。方法: 将72例复发性外阴阴道念珠菌病患者随机分为A、B两组, A组39例, 采用氟康唑胶囊0 15g口服, 1次/d, 连服7d, 停药观察; B组33例, 采用氟康唑胶囊0 15g口服, 1次/d, 连服7d治疗后, 于每月月经来潮前1d口服氟康唑胶囊0 3g一次, 连续用药半年。结果: A、B两组治疗1周后, 治愈率分别为87. 18%和87 88%, 无显著性差异(χ2 =0 .008, P>0. 05); 3个月、6个月、12个月各阶段复发率分别为20. 59%、0 .00%, 35 .29%、3 .45%, 47 .06%、6 .90%, 差异有显著性意义(χ2 =6. 72, P<0. 01; χ2 =9 .69, P<0 .001;χ2 =11. 84, P<0. 001)。结论: 氟康唑预防性治疗能够较好地阻断RVVC的复发。 Objective:To explore the preventive therapeutic effect of recurrent vulvovaginal candidiasis (RVVC).Methods:72 patients with RVVC were randomly divided into group A ( n =39) and group B ( n =33). 39 cases of group A were given Fluconazole capsules 0.15 g po qd for 7 days; 33 cases of group B were given Fluconazole capsules 0.3 g po once at a day before menses a month for 6 months.Results:The curative ratio of group A and group B at 1 week after treatment was 87.18% and 87.88%, respectively ( χ 2 =0.008, P >0.05); the curative ratio at 3, 6, 12 months of group A and B was 20.59%, 0.00%, 35.29%, 3.45%, 47.06% and 6.90% ( χ 2 =6.72, P <0.01; χ 2 =9.69, P <0.001; χ 2 =11.84, P <0.001).Conclusion:Preventive treatment with Fluconazole could effectively interdict the recurrence of RVVC.
出处 《中国妇幼保健》 CAS 北大核心 2005年第8期963-964,共2页 Maternal and Child Health Care of China
关键词 复发性外阴阴道念珠菌病 预防性治疗 氟康唑 Recurrent vulvovaginal candidiasis (RVVC) Preventive treatment Fluconazole capsules
  • 相关文献

参考文献2

二级参考文献23

  • 1刘自贵,中华医院感染学杂志 B,1997年,7卷,216页
  • 2Tang E,Arch Surg,1993年,128页
  • 3Fidel PL Jr, Lynch ME, Sobel JD. Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis.Infect Immun, 1993,61 (5): 1990 - 1995.
  • 4Fidel PL Jr, Lynch ME, Sobel JD. Effects of preinduced Candida-specific systemic cell-mediated immunity on experimental vaginal candidiasis. Infect Immun, 1994,62 (3): 1032 - 1038.
  • 5Fidel PL Jr, Lynch ME, Sobel JD. Circulating CD4 and CD8 T cells have little impact on host defense against experimental vaginal candidiasis. Infect Immun, 1995,63 (7) :2403 - 2408.
  • 6Cantoma M, Mook D, Balish E. Resistance of congenitally immunodeficient gnotobiotic mice to vaginal candidiasis. Infect Immun, 1990,58(11) :3813 -3815.
  • 7Fidel PL Jr, Lynch ME, Conaway DH, et al. Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity. Infect Immun, 1995, 63(2) :547 -553.
  • 8Taylor BN, Saavedra M, Fidel PL Jr. Local Thl/Th2 cytokine production during experimental vaginal candidiasis: potential importance of transforming growth factor-beta. Med Mycol, 2000, 38 (6):419 -431.
  • 9Saavedra M, Taylor B, Lukacs N, et al. Local production of chemokines during experimental vaginal candidiasis. Infect Immun, 1999,67(11):5820-5826.
  • 10Wormley FL Jr, Chalban J, Fidel PL Jr. Cell adhesion molecule and lymphocyte activation marker expression during experimental vaginal candidiasis. Infect Immun, 2001,69(8):5072 - 5079.

共引文献34

同被引文献63

引证文献11

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部